ClinicalTrials.Veeva

Menu

Iron and Retinopathy of Prematurity (ROP) (Fer-ROP)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Retinopathy of Prematurity

Treatments

Other: Fundus Examination by wide field digital imaging camera (PanocamTM camera)
Biological: Plasma determination of iron, transferrin and ferritin

Study type

Observational

Funder types

Other

Identifiers

NCT05133999
2021-A02182 (Other Identifier)
APHP211233

Details and patient eligibility

About

The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

Preterm infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be included. Iron parameters in plasma will be measured during the first month of life. Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship between plasma iron parameters and ROP development and/or severity will be established.

Full description

The incidence of ROP, the main cause of vision impairment in children, is increasing parallel to the recent changes in practices targeting higher oxygen saturation in preterm babies in many countries following the publication of five trials that showed higher rates of death with lower oxygen saturations. The main risk factor for ROP development is oxygen excess. Oxygen contributes to the formation of reactive oxygen species and to lipid peroxidation which leads to vasoconstriction, vascular cytotoxicity, and arrest of vascular development causing ischemia of retinal neurons, thereby promoting the development of ROP.

90% of extremely low birth weight infants need red blood cell transfusions (RBCT) due to their immature erythropoiesis, frequent blood sampling and small circulating blood volume. RBCT are a major source of iron overload and ferritin plasma levels may remain elevated for several weeks after transfusions. It has been shown that blood transfusion is a risk factor of ROP in preterm infants. However, whether this relationship is mediated by an increased iron load remains controversial.

Only two studies, conducted before the 2000s, identified plasma iron overload as a risk factor for ROP. These studies with a limited number of patients, showed contradictory results, failing to draw a conclusion.

Excess iron worsens oxidative stress. Iron catalyzes the Fenton reaction which leads to the formation of reactive oxygen species. In addition a transferrin deficiency (the main iron chelator) has been suggested in premature infants. The oxidative stress observed in ROP could therefore be the consequence not only of oxygen therapy but also of iron overload.

The main objective of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

The secondary aims/objectives are :

  • Determine whether low transferrin level in plasma is an independent risk factor for ROP development and severity.
  • Determine whether iron parameters imbalance in plasma are a risk factor for other comorbidities in Preterm infants i.e.:
  • 1) sepsis
  • 2) severe bronchopulmonary dysplasia
  • 3) necrotizing enterocolitis (stage 2 or 3)
  • 4) cystic periventricular leukomalacia
  • 5) grade III or IV intraventricular haemorrhage

Study duration will be 29 months, with an inclusion period of 24 months and a last visit for ROP evaluation at 45 week's post-menstrual age (PMA).

A total of 175 patients should be included: 35 with ROP and 140 without ROP.

Enrollment

175 patients

Sex

All

Ages

24 to 31 weeks old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birthweight
  • Admitted at two neonatology departments (level III) from birth
  • With non-opposition consent of two parents

Exclusion criteria

  • Congenital malformation
  • Life-threatening condition (not expected to survive more than a few days)
  • Absence of health care protection.

Trial design

175 participants in 1 patient group

Preterm infants
Description:
infants born at \<31 week's post-menstrual age (PMA) or ≤1250g of birth weight
Treatment:
Biological: Plasma determination of iron, transferrin and ferritin
Other: Fundus Examination by wide field digital imaging camera (PanocamTM camera)

Trial contacts and locations

3

Loading...

Central trial contact

Prissile BAKOUBOULA, PhD; Alejandra DARUICH, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems